Cargando…
Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis
BACKGROUND: COVID-19 vaccination is essential. However, no study has reported adverse events (AEs) after ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease (ESRD) on hemodialysis (HD). This study investigated the AEs within 30-days after the first dose of ChAdOx1 nCoV19 (Oxford-Ast...
Autores principales: | Yang, I-Ning, Lu, Chin-Li, Tang, Hung-Jen, Kuo, Yu-Chi, Tsai, Li-Hwa, Tu, Kuan Chieh, Wang, Jhi-Joung, Chien, Chih-Chiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462771/ https://www.ncbi.nlm.nih.gov/pubmed/36084024 http://dx.doi.org/10.1371/journal.pone.0273676 |
Ejemplares similares
-
Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
por: Lin, Ting-Yun, et al.
Publicado: (2022) -
Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis
por: Ling, Tsai-Chieh, et al.
Publicado: (2023) -
Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021) -
Myocardial Infarction and Azygos Vein Thrombosis After ChAdOx1 nCoV-19 Vaccination in a Hemodialysis Patient
por: Chiang, Chun-Yen, et al.
Publicado: (2021) -
Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)